Dementia experts have hailed the latest landmark in the treatment of the condition after Eli Lilly released trial results that showed its new Alzheimer’s drug significantly slowed memory loss and cognitive decline.
The US pharmaceuticals group on Monday reported full findings of its phase 3 clinical study of donanemab at the Alzheimer’s Association International Conference in Amsterdam, showing that the antibody treatment slowed progression by about 35 per cent in the early stages of the disease.
The peer-reviewed results follow similar phase 3 findings released last November by US biotech Biogen and Japan’s Eisai for lecanemab, another antibody drug, which received full marketing approval from the US Food and Drug Administration this month under the brand name Leqembi.